Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Inmune Bio is a clinical-stage biotechnology company focused on reprogramming the innate immune system. Its lead program, CORDStrom, targets Recessive Dystrophic Epidermolysis Bullosa (RDEB) and has completed a pivotal trial, with regulatory submissions (MAA/BLA) targeted for 2026. The company also maintains pipelines for XPro1595 (Alzheimer's Disease) and INKmune (Oncology).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $50 | $14 |
| Net Loss | $(45,933) | $(42,082) |
| Research & Development Expense | $20,659 | $33,166 |
| General & Administrative Expense | $10,260 | $9,483 |
| Impairment of Intangible Assets | $16,514 | $0 |
| Cash and Cash Equivalents (Year End) | $24,751 | $20,922 |
| Accumulated Deficit | $(209,037) | $(163,104) |
| Net Cash Used in Operating Activities | $(22,582) | $(33,361) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $3.9 million to $45.9 million, primarily driven by a one-time $16.5 million impairment charge related to the XPro1595 (Alzheimer's) program following Phase 2 results.
- R&D Expense Decrease: R&D expenses decreased by $12.5 million (38%) to $20.7 million. This reduction was due to the completion of the Phase 2 Alzheimer's trial and higher accrued tax rebates, partially offset by increased costs for the CORDStrom and INKmune programs.
- Impairment Event: The company recorded a full impairment of acquired in-process research and development intangible assets ($16.5 million) after determining the fair value of the XPro1595 asset was zero due to insufficient resources to fund further independent development.
- Liquidity Position: Cash balances increased by $3.8 million to $24.8 million, supported by net financing proceeds of $27.6 million from equity offerings (Registered Direct Offering and ATM sales).
Guidance, Outlook, and Risks
Outlook and Strategy
- CORDStrom: The company intends to file a Marketing Authorization Application (MAA) in the UK and EU in 2026, followed by a Biologics License Application (BLA) with the FDA in late 2026. The program has received Rare Pediatric Disease and Orphan Drug Designations.
- XPro1595: Due to capital constraints and the Phase 2 primary endpoint miss, the company has halted independent development and is seeking a strategic partner to advance the program.
- INKmune: The Phase II trial for metastatic castrate-resistant prostate cancer is fully enrolled; however, the company does not intend to move this program further into development without external capital or partnership.
Risks and Contingencies
- Going Concern: The filing includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management projects that current cash resources ($24.8 million) are insufficient to sustain operations for one year following the issuance of the financial statements.
- Capital Requirements: The company requires additional funding to advance CORDStrom to commercialization. Failure to secure financing could result in scaling back or discontinuing operations.
- Regulatory Risk: Success is heavily dependent on obtaining regulatory approval for CORDStrom, which is not guaranteed.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash burn and the status of any new financing agreements post-filing to assess the immediate risk of insolvency.
- XPro1595 Partnership: Confirm if a strategic partner has been identified to take over the Alzheimer's program, as this could unlock value or provide necessary capital.
- CORDStrom Regulatory Timeline: Monitor the status of the Type C meeting with the FDA and the planned submission dates for the UK/EU MAAs and US BLA in 2026.
- Equity Dilution: Review the terms of the new ATM agreement with A.G.P./Alliance Global Partners and the potential for further dilution required to fund operations.
- Going Concern Mitigation: Assess management's specific plans to alleviate the substantial doubt expressed by the auditors, including potential asset divestitures or licensing deals.